Figure 7. IL31 therapy enhances the anti-cancer activity of paclitaxel chemotherapy.

LM2-4 human breast carcinoma cells (2 × 10⁶) were implanted into the mammary fat pad of 6–8 week old NOD-SCID mice (n = 4–5 mice/group). When tumors reached a size of 50 mm³, treatment with paclitaxel (PTX) or PTX+IL31-IgG was initiated. (A) Tumor growth was assessed over time. (B) Tumors were removed at end point and sectioned. Tumor sections were immuno-stained with CD31 (red). Nuclei were stained with DAPI (blue). Scale bar = 200 μm. Microvessels per field (n > 15 fields/group) were quantified. (C) Lungs were removed and sectioned. Lung sections were stained with H&E to visualize metastatic lesions (red arrows). Representative images are shown. Scale bar = 200 μm. Metastatic lesions per field were counted (n > 10 fields/group) *,0.05 > p > 0.01; **, 0.01 > p > 0.001; ***p < 0.001.